Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | DRD3 | P35462 | 5/20 | 0.51 |
| ▸ | DRD1 | P21728 | 3/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | DRD5 | P21918 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7656340 | 0.91 | CYP2D6 (0.59) | HTR1ADRD2DRD3DRD1HTR2A | |
| SCHEMBL4447104 | 0.87 | DRD2 (0.58) | HTR1ADRD2DRD3DRD1HTR2A | |
| SCHEMBL26108581 | 0.82 | HTR1A (0.65) | HTR1ADRD2DRD3DRD1HTR2A | |
| SCHEMBL26492991 | 0.82 | HTR1A (0.65) | HTR1ADRD2DRD3DRD1HTR2A | |
| SCHEMBL23252522 | 0.81 | HTR1A (0.53) | HTR1AMEN1KMT2ADRD2DRD3 | |
| Hydrochloric Acid SCHEMBL26108377 | 0.81 | DRD2 (0.63) | HTR1ADRD2DRD3DRD1HTR2A | |
| SCHEMBL3910170 | 0.81 | LMNA (0.57) | HTR1AMEN1KMT2ADRD2DRD3 | |
| SCHEMBL7488861 | 0.81 | MEN1 (0.56) | HTR1AMEN1KMT2ADRD2DRD3 | |
| SCHEMBL6399783 | 0.81 | MEN1 (0.58) | HTR1AMEN1KMT2ADRD2DRD3 | |
| SCHEMBL5652648 | 0.81 | HTR1A (0.55) | HTR1AMEN1KMT2ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| WO-2021011670-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | disclosed |
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| EP-0526434-A1 | Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1993-02-03 | — | — | EP | disclosed |
| US-5106849-A | Treating anxiety, depression, psychoses | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-04-21 | — | — | US | disclosed |
| WO-1991010664-A1 | PYRIDAZINO[4,5-b]INDOLIZINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-07-25 | — | — | WO | disclosed |
| US-5010078-A | Anxiolytic, antidepressant agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-04-23 | — | — | US | disclosed |
| US-4988814-A | Antidepressants and/or anxiolytic agents | AMERICAN HOME PRODUCTS CORP. (US) | 1991-01-29 | — | — | US | disclosed |
| US-4985560-A | Pyridazino(4,5-b)indolizines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-01-15 | — | — | US | disclosed |
| EP-0395313-A2 | Tertiary alkyl functionalized piperazine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-10-31 | — | — | EP | disclosed |
| EP-0343961-A2 | Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-11-29 | — | — | EP | disclosed |
| US-4668687-A | Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones | BRISTOL-MYERS COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | POLB 3939/4885HTR1A 709/4885MEN1 2128/4885 |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | POLB 2640/4885HTR1A 1284/4885MEN1 323/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | POLB 3327/4885HTR1A 1491/4885MEN1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.